文献速递姑息放疗与转移瘤

定义接受姑息性放射治疗患者的预期30天死亡率:一项Meta分析

Defining the expected 30-day mortality for patients undergoing palliative radiotherapy: A meta-analysis.
PubMed 文献 · Radiother Oncol · 2022-01-29

该Meta分析纳入42项研究、88516例接受姑息性放射治疗的晚期癌症患者,汇总30天死亡率为16%(95%CI 14%至18%),异质性I²=98.76%(p<0.001);亚组分析显示多部位治疗、肝胆原发、住院状态、ECOG 3-4及美国患者等组30天死亡率更高;作者认为该结果可作为放疗科实践审计的全球质量指标基准。

要点

  • 接受姑息性放射治疗的晚期癌症患者30天死亡汇总比例为16%(95%CI 14%至18%)。
  • 数据异质性高(I²=98.76%,p<0.001),亚组分析显示多部位治疗、肝胆原发、住院状态、ECOG 3-4及美国患者组30天死亡率更高。
  • 作者认为该16%可作为建立放疗科实践审计全球质量指标的基准。

核心结论

  • 接受姑息性放射治疗的晚期癌症患者中16%在治疗开始后30天内死亡。
  • 作者认为该发现可作为建立放疗科实践审计全球质量指标的基准。

研究设计与样本

  • 检索MEDLINE、CINAHL、Embase和Cochrane系统评价数据库,时间范围为1980年1月1日至2020年6月26日,并补充PubMed相关检索和参考文献列表。
  • 纳入报告接受姑息性放射治疗的晚期癌症患者30天死亡率的已发表和未发表英文随机对照试验、观察性或前瞻性研究及系统评价。
  • 数据由两名独立作者提取,包括研究质量指标;采用logit转换处理比例,使用随机效应模型(Der Simonian和Laird法)合并数据。
  • 最终纳入42项研究、88516例接受姑息性放射治疗的晚期癌症患者。

主要发现

  • 接受姑息性放射治疗的晚期癌症患者30天死亡汇总比例为16%(95%CI 14%至18%)。
  • 数据存在显著异质性(I²=98.76%,p<0.001),因此进行亚组分析以识别潜在调节因素。
  • 以下组别接受姑息性放射治疗后30天死亡率更高:多部位治疗(QM(1)=9.54,p=0.002)、肝胆原发(QM(1)=24.20,p<0.001)、住院状态(QM(1)=92.27,p<0.001)、ECOG 3-4(QM(1)=8.70,p=0.003)、美国患者(QM(1)=28.70,p<0.001)等。

临床怎么用

  • 作者认为该16%的30天死亡率可作为建立放疗科实践审计全球质量指标的基准。

局限性

  • 数据存在显著异质性(I²=98.76%,p<0.001)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The expected 30-day mortality rate for patients treated with palliative radiationisnotestablished. The primary objective of this study is todefinetheproportion of patientswith advanced cancerwho diewithin 30-daysofpalliative radiotherapy(PR). Additionally, we explored the short term survival of patient subgroups undergoing PR treatment. METHODS: We searched MEDLINE, CINAHL, Embase and Cochrane Database of Systematic Reviews from January 1st 1980 to June 26, 2020. We included PUBMED's related search and reference lists to further identify articles. A meta-analysis of these research studies and reviews was performed. Published and unpublished English language randomized controlled trials, observational or prospective studies, and systematic reviews that reported 30-day mortality for patients with advanced cancer who received PR were eligible. Data extraction was done by two independent authors and included study quality indicators. To improve distribution and variance, all proportions were transformed using logit transformation. A random-effects model was used to pool data, using Der Simonian and Laird method of estimation where possible and appropriate. RESULTS: The data from 42 studies contributing 88,516 patients with advanced cancer who received PR were evaluated. The summary proportion of mortality in patients with advanced cancer within 30 days of receiving PR was 16% (95% CI = 14% to 18%). We found substantial heterogeneity in our data (I2 = 98.76%, p < 0.001), hence we applied subgroup analysis to identify potential moderating factors. We found a higher 30-day mortality rate after PR in the following groups: multiple treatment sites (QM(1) = 9.54, p = 0.002), hepatobiliary primary (QM(1) = 24.20, p < 0.001), inpatient status (QM(1) = 92.27, p < 0.001), Eastern Cooperative Oncology Group performance status (ECOG) 3-4 (QM(1) = 8.70, p = 0.003), United States (U.S.) patients (QM(1) = 28.70, p < 0.001) among others. CONCLUSIONS: We found that 16% of patients with advanced cancer receiving PR die within 30 days of treatment. Our findingcan be used asabenchmarktoestablishaglobal quality metric for radiation oncology practice audits.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Kutzko JH, Dadwal P, Holt T, et al. Defining the expected 30-day mortality for patients undergoing palliative radiotherapy: A meta-analysis. Radiother Oncol. 2022. PMID: 35101462. doi:10.1016/j.radonc.2022.01.030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。